{
    "Clinical Trial ID": "NCT00546104",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Dasatinib",
        "50mg-100mg po BID"
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  Measurable Stage IV or inoperable Stage III advanced breast cancer.",
        "  There is no limit on the number of prior therapies.",
        "  At least 3 weeks since prior chemotherapy, biological or hormonal therapy.",
        "  At least 2 weeks since surgical biopsy.",
        "  At least 3 weeks since major (open thoracic/abdominal/cardiac) surgery.",
        "  No central nervous system (CNS) metastases except solitary brain metastasis",
        "  No cardiac dysfunction",
        "  left ventricular ejection fraction (LVEF)  50% as determined by multiple gated acquisition scan (MUGA)/echocardiogram",
        "  Adequate blood counts",
        "  Normal liver and kidney function",
        "  Negative serum pregnancy test.",
        "  Able to provide informed consent",
        "Exclusion Criteria:",
        "  Pregnant or breast feeding.",
        "  Prior treatment with dasatinib.",
        "  Bone as the only site of disease.",
        "  Significant gastrointestinal bleeding",
        "  Septicemia, infection, acute hepatitis, hypokalemia, or hypomagnesemia"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Estimation of the Proportion of Progression-free Patients at 16 Wks.",
        "  Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or measurable increase in a non-target lesion, or the appearance of new lesions, or similar definition as appropriate.",
        "  Proportion progression-free at 16 weeks.From first day of study related treatment with Dasatinib until the date of first documented progression or date of death from any cause, whichever came first.",
        "  Time frame: 16 weeks",
        "Results 1: ",
        "  Arm/Group Title: Dasatinib",
        "  Arm/Group Description: 50mg-100mg po BID",
        "  Overall Number of Participants Analyzed: 31",
        "  Measure Type: Number",
        "  Unit of Measure: percentage of participants  0        (0 to 20)"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 10/31 (32.26%)",
        "  Edema, limb 1/31 (3.23%)",
        "  Thrombosis1/31 (3.23%)",
        "  diarrhea1/31 (3.23%)",
        "  Pain 2/31 (6.45%)",
        "  Pain, back1/31 (3.23%)",
        "  Pain, extrimity limb 1/31 (3.23%)",
        "  Syncope 1/31 (3.23%)",
        "  Pain, chest/thorax1/31 (3.23%)",
        "  hyponatremia 1/31 (3.23%)",
        "  fever1/31 (3.23%)",
        "  AST 1/31 (3.23%)",
        "  infection1/31 (3.23%)",
        "  Anorexia 1/31 (3.23%)",
        "  Dyspnea 2/31 (6.45%)"
    ]
}